Mexico Breast Cancer Therapeutics Market Report 2022 to 2030

Mexico Breast Cancer Therapeutics Market Analysis

$ 3999

As new targeted therapies are being developed in Mexico, there is significant growth being observed in the Mexico breast cancer therapeutics market from $273 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the forecasted year 2022-30. The market is segmented by therapy, by cancer type, and by distribution channel. Lupin, Sanofi, and Teva Pharmaceuticals are some of the major competitors in the Mexico breast cancer therapeutics market.

ID: IN10MXPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Mexico AUTHOR: Parul Choudhary

Buy Now

Mexico Breast Cancer Therapeutics Market Executive Analysis

Mexico's breast cancer therapeutics market from $273 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the forecasted year 2022-30. More than $1 trillion pesos, or around 60% of all healthcare spending in 2021, was spent on healthcare by Mexican households in 2022. The country's total healthcare spending decreased from 6.5% of GDP in 2020 to 6.2% last year. The share of public healthcare spending in the GDP was only 2.5 %. The Organization for Economic Co-operation and Development (OECD) forecasts that in 2021, overall healthcare spending in the United States accounted for 17.8% of the country's GDP, the highest proportion among its 38 members. 2.9% of these were classified as "voluntary" private health expenses. Spending on medications and other items accounted for 50.7% of all healthcare-related products and services consumed by households. Hospital services come in second at 14%, followed by other healthcare-related services at 5.7%, then medical consultations and support products and services, such as health insurance premiums, at 14.8%.

Breast cancer is the second most common cause of cancer-related deaths among women in Mexico and the most prevalent malignancy in the country. In Mexico, the prevalence of breast cancer has been rising in recent years, with greater rates in the nation's more developed regions. Aging, a family history of the disease, and particular lifestyle variables including obesity and alcohol usage are all risk factors for breast cancer in Mexico. To improve outcomes for patients with breast cancer in Mexico, early detection and treatment are essential. Immunotherapy, commonly referred to as cellular therapy, is a natural autologous cellular therapy used to suppress and eradicate aggressive breast cancer cells. It makes use of dendritic cells, natural killer cells (NK cells), and lymphokine-activated killer cells (LAK cells). Due to its high efficacy and capacity for synergy, immunotherapy for breast cancer patients has gained medical approval and has emerged as one of the top cancer management medicines utilized by Mexico's leading oncologists. Due to its low risk and reasonable price, this therapy is one of the most widely used therapies for treating breast cancer. Patients looking for chemotherapy alternatives will find it to be an excellent alternative.

Mexico breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

A huge number of new targeted therapies are being developed for various types of cancers as a result of recently discovered biology and genetic knowledge, which is causing the Mexico breast cancer therapeutics market to expand. The development of novel trial designs, rapid developments in cancer research, and expanding knowledge of the biology and pharmacology of cancer cells are all contributing to the Mexico breast cancer therapeutics market expansion.

Market Restraints

It is anticipated that the high costs of breast cancer therapies, rising expenses of immunotherapies and targeted therapies, and the side effects of breast cancer drugs would inhibit the expansion of the Mexico breast cancer therapeutics market.

Competitive Landscape

Key Players

Chiesi Farmaceutici (MEX)
Esteve Química (MEX)
GBT Grupo Biotoscana (MEX)
Lupin (MEX)
Sanofi
Teva Pharmaceutical
GlaxoSmithKline
Amgen
Merck

Healthcare Policies and Regulatory Landscape

Through the Instituto Mexicano del Seguro Social (IMSS) and the Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), the government offers health insurance to people. For those who qualify, these organizations will pay the expenses associated with breast cancer treatment. Depending on the type of treatment, different payment policies may apply, and some therapies may not even be covered. Additionally, patients can be required to pay out-of-pocket for a portion of their care and might need to fulfill criteria in order to qualify for reimbursement. Some private health insurance plans in Mexico may also cover the cost of breast cancer treatment in addition to government-provided coverage. These policies, however, can have restrictions or exclusions, and the coverage might differ based on the plan.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.